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Abstract Radiolabelled receptor-binding peptides targeting
receptors (over)expressed on tumour cells are widely under
investigation for tumour diagnosis and therapy. The concept
of using radiolabelled receptor-binding peptides to target
receptor-expressing tissues in vivo has stimulated a large
body of research in nuclear medicine. The
111In-labelled
somatostatin analogue octreotide (OctreoScan™)i st h e
most successful radiopeptide for tumour imaging, and was
the first to be approved for diagnostic use. Based on the
success of these studies, other receptor-targeting peptides
such as cholecystokinin/gastrin analogues, glucagon-like
peptide-1, bombesin (BN), chemokine receptor CXCR4
targeting peptides, and RGD peptides are currently under
development or undergoing clinical trials. In this review, we
discuss some of these peptides and their analogues, with
regard to their potential for radionuclide imaging of tumours.
Keywords Radiolabelled receptor-bindingpeptides.
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Introduction
Radiolabelled receptor-binding peptides have emerged as an
important class of radiopharmaceuticals for tumour diagno-
sis and therapy. The concept of using radiolabelled receptor-
binding peptides to target receptor-expressing tissues in vivo
has stimulated a large body of research in nuclear medicine.
Small peptides for receptor imaging and targeted radiother-
apy have advantages over proteins, antibodies and antibody
fragments. Peptides are small molecules and show rapid
diffusion in target tissue. Due to their low molecular weight
they clear rapidly from the blood and non-target tissues,
resulting in high tumour-to-background ratios. In addition,
peptides generally are non-immunogenic. Peptides have
been labelled for use with SPECT and PET. Commonly
used gamma emitters used for peptide labelling are
111In
and
99mTc. For PET imaging, peptides can be radiolabelled
with positron emitting radionuclides such as
68Ga,
18F and
64Cu. Radiolabelled receptor-binding peptides can be used
to noninvasively visualize receptor-expressing tissues, a
technique referred to as peptide-receptor radionuclide imag-
ing. To date, the
111In-labelled somatostatin analogue
octreotide (OctreoScan™) is the most successful radiopep-
tide for tumour imaging, and was the first to be approved for
diagnostic use. It is considered the diagnostic gold standard
for imaging several types of neuroendocrine tumours. Other
receptor-targeting peptides such as cholecystokinin (CCK)/
gastrin analogues, glucagon-like peptide-1 (GLP-1), BN,
chemokine receptor CXCR4 targeting peptides, and RGD
peptides are currently under development or undergoing
clinical trials. Here, we discuss some of the most widely
studied peptides, other than peptides targeting somatostatin
receptors (SSTR) and their potential for radionuclide imag-
ing of tumours.
CCK peptides
CCK is a peptide hormone, originally discovered in the
gastrointestinal tract by Ivy and Oldberg [1]. In 1975,
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London EC1M 6BQ, UKCCK was described as a gastrin-like immunoreactive pep-
tide and as one of the most widespread neuropeptides in the
central nervous system [2]. CCK exerts various physiolog-
ical actions in the gastrointestinal tract and in the central
nervous system. CCK was initially characterized as a 33-
amino acid sequence, but the peptide was shown to be
present in a variety of biologically active molecular forms
such as CCK39, CCK33, CCK8 and CCK4, all derived
from a 115-amino acid precursor molecule. The most abun-
dant peptide in the brain is CCK8 (Asp-Tyr-Met-Gly-Trp-
Met-Asp-Phe-NH2)[ 3, 4].
Receptors for CCK have been pharmacologically classi-
fied based on their affinity for the endogenous peptide CCK
and gastrin. These two ligands share the same amidated C-
terminal pentapeptide sequence but differ in sulphation of
the tyrosine residue at position 6 (gastrin) or 7 (CCK) [5, 6].
Three types of CCK receptors have been identified. The
CCK1 (formerly known as CCK-A) receptor was first char-
acterized in pancreatic acinar cells [7], and is mainly located
in the periphery. The CCK2 (formerly known as CCK-B)
receptor was discovered in the brain [8] and is expressed in
the brain and in the stomach, pancreas and gallbladder. In
the gastrointestinal tract, activation of this receptor by gas-
trin stimulates gastric acid secretion [4]. The third type of
CCKreceptoristheCCK2i4svreceptor,asplicevariantofthe
CCK2receptor, first isolatedand characterized byHellmichet
al. [9]. This receptor is generated by intron 4 retention during
RNA processing, resulting in a 69-amino acid insert in the
third intracellular loop domain of the receptor [9]. The
CCK2i4sv receptor was discovered in human colorectal can-
cer cells and stimulates cell growth through a gastrin-
independent mechanism.
The CCK1 and CCK2 receptor have been shown to differ
by their affinity for gastrin binding, their differential distri-
bution and their molecular structure. The CCK1 receptor
binds sulphated CCK with a 500- to 1,000-fold higher
affinity than nonsulphated CCK. The CCK2 receptor binds
gastrin and CCK with almost the same affinity and does not
discriminate between the sulphated and nonsulphated CCK
analogues [3]. The CCK2 receptor is therefore also referred
to as the gastrin receptor.
Tumour expression of CCK receptors
CCK1 and CCK2/gastrin receptors have been identified in
several normal tissues and in various tumours. Reubi and
Waser identified an unexpectedly high incidence (>90%) of
CCK2 receptors in medullary thyroid carcinomas (MTC),
whereas differentiated thyroid cancers do not express CCK2
receptors [10]. MTCs comprise 3–12% of all thyroid can-
cers. In addition, CCK2 receptors are frequently found in
astrocytomas (65%) and stromal ovarian cancers (100%).
CCK1 receptors are expressed rarely in human tumours
[11]. The splice variant of the CCK2 receptor, the
CCK2i4sv receptor, is expressed in human colorectal can-
cers and pancreatic cancers, but not in normal colorectal
mucosa [9, 12]. However, expression levels of the
CCK2i4sv receptor may be too low to allow efficient target-
ing with radiolabelled peptides, as a recent study showed
rarely any expression of CCK2i4sv mRNA in pancreatic,
gastric and colorectal carcinomas [13].
Several research groups have aimed to develop suitable
radioligands for targeting the CCK2 receptor in vivo. A
variety of radiolabelled CCK/gastrin-related peptides have
been synthesized and characterized. All peptides have in
common the C-terminal CCK receptor-binding tetrapeptide
sequence Trp-Met-Asp-Phe-NH2 or derivatives thereof. The
presence of an intact C-terminal sequence has been shown
to be crucial for receptor binding, although the methionine
may be replaced by leucine or norleucine without affecting
receptor binding affinity [5, 14].
Preclinical studies with radiolabelled CCK2R-binding
ligands
In the late 1990s, Behr et al. showed promising results with
131I-radioiodinated human gastrin-I in diagnostic and thera-
peutic applications [14]. This synthetic heptadecapeptide
has a low nanomolar affinity for CCK2 receptors, whereas
its affinity to CCK1 receptors is at least four orders of
magnitude lower. Behr et al. investigated a series of 18
radioiodinated gastrin and CCK derivatives for targeting
C C Kr e c e p t o r si nv i v o[ 5]. They found that sulphated
CCK analogues and some nonsulphated gastrin analogues
displayed the highest affinities (IC50 values in the nano-
molar range), whereas desulphation or the complete removal
of the N-terminally located tyrosine of the peptide led to a
loss of affinity.
Reubi et al. developed a series of nonsulphated CCK8
analogues which were N-terminally conjugated with dieth-
ylenetriaminepentaacetic acid (DTPA) or 1,4,7,10-tetraaza-
cyclododecane-1,4,7,10 tetraacetic acid (DOTA) to allow
radiometalbinding[15].Theyfoundahighspecificitytowards
CCK2 receptors, which was determined by the presence of
nonsulphated tyrosine. Analogues in which methionine in
position 3 and 6 was replaced by norleucine—to prevent
oxidation causing a loss of affinity—had similarbindingprop-
erties (IC50 1.5 nM) to those of native CCK8 (IC50 2.3 nM)
and showed increased plasma stability. These analogues
showed promising results in non-tumour-bearing rats: rapid
clearance by renal excretion, increased plasma stability and
low uptake and retention in the main peripheral soft tissues.
Based on this study, Reubi et al. concluded that nonsulphated
CCK analogues are highly promising for CCK2 receptor
scintigraphy.
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111In-DOTA-CCK8[Nle
3,6] for peptide receptor radionu-
clide therapy (PRRT) [16]. Internalization, biodistribution
and tumour targeting were studied and a receptor-specific
and time- and temperature-dependent internalization of
111In-DOTA-CCK8 in AR42J cells (rat pancreatic tumour)
was demonstrated. Evaluation in a syngeneic rat tumour
model showed good targeting of CA20948 tumours (rat
pancreatic tumour). Uptake of
111In-DOTA-CCK8[Nle
3,6]i n
CCK2 receptor-expressing tissues was specific and uptake in
receptor-negative organs was low.
We studied two
99mTc-labelled CCK8 analogues for scin-
tigraphic imaging of CCK receptors, nonsulphated CCK8
(nsCCK8) and sulphated CCK8 (sCCK8) [17]. We demon-
strated that uptake of the sulphated analogue,
99mTc-tricine/
HYNIC-sCCK8, in both CCK1 and CCK2 receptor-
expressing tumours in mice was approximately 15-fold
higher than that of the nonsulphated analogue. More recently,
we showed that
111In-labelled DOTA-sCCK8 and DOTA-
minigastrin (MG0) also have affinity for the splice variant of
the CCK2 receptor, the CCK2i4sv receptor [18]. Tumour
uptake of
111In-labelled DOTA-sCCK8 in CCK2i4sv
receptor-positive tumours was similar to the uptake in CCK2
receptor-expressing tumours.
In 2004, Aloj et al. reported results obtained with
111In-DTPA-Glu-Gly-CCK8 using DTPA as a chelator
[19, 20]. They used the same chelator Béhé et al. used
in their earlier studies with minigastrin [21]. A glycine
residue was introduced as a spacer between the chelator and
the peptide. The peptide conjugate showed good affinity for
the CCK2 receptor. In line with the results of Béhé et al.,
chelation of
111In was found to be more stable than with
conventional DTPA. Tumour uptake of
111In-DTPA-Glu-G-
CCK8 in A431-CCK2R xenografts was 4%ID/g at 30 min
after injection [19].
Three
99mTc-labelled minigastrin analogues were inves-
tigated by Nock et al. for targeting the CCK2/gastrin recep-
tor [22]. They derivatized minigastrin with an open-chain
tetraamine either directly (Demogastrin 1) or via different
spacers (Demogastrin 2 and 3), to achieve stable labelling
with
99mTc. After injection in mice, tumour-to-nontarget
r a t i o sw e r ef a v o u r a b l ef o r
99mTc-Demogastrin 2 (with a
glycine between the chelator and the peptide). The high
kidney uptake could be reduced by coinjection of poly-
Glu-containing peptides. Similar observations were reported
by Béhé et al. after intraperitoneal injection of poly-Glu
peptides in rats [23].
Mather et al. aimed to identify a radioligand that com-
bined the relatively high tumour uptake of peptides belong-
ing to the gastrin family with the low renal uptake seen with
CCK derivatives [24]. They prepared a library of DOTA and
DTPA peptide conjugates based on the C-terminal structure
of minigastrin. Removal of the pentaglutamate sequence
present in minigastrin resulted in a strong reduction in
kidney uptake from 60%ID/g to 3%ID/g, but also reduced
tumour uptake by a factor of 3. Replacement of the penta-
glutamate sequence in minigastrin with a hexahistidine tag
resulted in a similar reduction in kidney and tumour uptake.
They found that a dihistidine analogue (DOTA-His-His-
Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) showed the best
results in terms of tumour-to-kidney ratio, with a Ki value
of 3.9 nM. Radiolabelling of these analogues, however,
needed heating to 100°C, resulting in a high level of oxida-
tion of the methionine residues. The most effective, clini-
cally acceptable antioxidant to overcome this problem was
monothioglycerol. Substitution of the methionine residue
with nonoxidizable norleucine lowered both in vitro recep-
tor affinity and in vivo tumour uptake. These findings are in
contrast with those of Reubi et al. in their study on CCK8
analogues [15] and with our findings [25]. In the search for
stabilized sCCK8 analogues, we synthesized peptides in
which the methionine residues were replaced by either nor-
leucine or homopropargylglycine to prevent oxidation. Fur-
thermore, the sulphated tyrosine was replaced by a stable
synthetic isostere, phenylalanine sulphonate. In vitro studies
showed that the peptides were resistant to oxidation, where-
as the affinity was retained in the low nanomolar range.
Biodistribution studies in AR42J tumour-bearing mice
showed a tumour uptake of
111In-DOTA-sCCK8[Phe
2(p-
CH2SO3H),Nle
3,6] comparable to that of
111In-DOTA-
sCCK8. Imaging was performed with
111In-DOTA-sCCK8
[Phe
2(p-CH2SO3H),Nle
3,6] and with the lead compound
111In-DOTA-sCCK8 (Fig. 1).
Good et al. reported a decreased circulatory half-life and
lower tumour uptake of
111In-DOTA-MG11 (D-Glu-Ala-
Tyr-Gly-Trp-Met-Asp-Phe-NH2)i nm i c ei nc o m p a r i s o n
with
111In-DTPA-MG0 (D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-
Met-Asp-Phe-NH2)[ 26]. Although tumour-to-kidney ratios
were higher for
111In-DOTA-MG11, the absolute tumour
uptake in AR42J tumours was lower. Béhé et al. showed
that the high renal uptake of
111I n - D T P A - M G 0i nm i c e
could be significantly reduced by coinjection of polygluta-
mic acids, whereas tumour uptake was not impaired [23].
Linear gastrin analogues exist under various folded con-
formations in solution. As cyclization was shown to im-
prove the in vivo characteristics of other peptides such as
RGD analogues [27, 28], von Guggenberg et al. designed
and evaluated two cyclic minigastrin analogues (cyclo-MG),
based on MG11 [29]. They synthesized two MG analogues
containing unnatural amino acids in the peptide chain and a
cyclic constraint introduced through an internal amide bond.
The peptides were N-terminally conjugated with HYNIC to
allow
99mTc labelling. In vitro studies showed that receptor
binding was impaired by cyclization, possibly related to the
reduced flexibility of the peptide backbone. However, inter-
nalization of both cyclic MG analogues in AR42J cells was
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99mTc-HYNIC-MG11. Tumour up-
take of >3%ID/g at 1 h after injection was observed in nude
mice with subutaneous AR42J tumours for both analogues,
whereas the linear MG1 (
99mTc-HYNIC-γ-D-Glu-Ala-Tyr-
D-Lys-Trp-Met-Asp-Phe-NH2) analogue showed a very low
tumour uptake of <0.3%ID/g. More recently, these cyclized
peptides were conjugated with DOTA, to allow radiolabel-
ling with
68Ga and
111In [30]. Cyclization was reported to be
important to maximize tumour uptake of this peptide, but
did not improve the overall pharmacokinetic profile.
Stabilization of the peptide requires further optimiza-
tion to obtain a radioligand suitable for diagnostic and/
or therapeutic applications. Stabilization could possibly
also be achieved by dimerization of MG11. Sosabowski
et al. synthesized MGD5, a DOTA-conjugated dimeric
gastrin peptide [31]. The Kd of the dimeric peptide was
0.69 nM as compared to 2.9 nM for the monomeric
111In-APH070 peptide. In addition, the internalization
rate of
111In-MGD5 was nearly double that of
111In-
APH070. SPECT/CT imaging and biodistribution studies
have revealed that
111In-MGD5 has a clearly higher tumour
uptake than
111In-APH070.
Recently, the biodistribution and in vitro characteristics
of 12 CCK2R-targeting peptides have been investigated in a
collaborative effort by various research groups [32–34].
These studies indicated that three peptides are optimal since
they combined high tumour uptake with low kidney reten-
tion. Besides the above-mentioned cycloMG1 and dimeric
MGD5 peptides, the linear minigastrin analogue PP-F-11
showed good in vivo characteristics. In this peptide the
five N-terminal L-Glu residues of MG0 are replaced by six
D-Glu residues [35], resulting in a kidney uptake only one-
tenth that of MG0. Potentially the stability of these peptides
could be further improved. Ocak et al. [34] found variable
stability of the various gastrin peptides with serum half-lives
ranging from 4.5±0.1 h to 198±0.1 h. In the urine of mice,
only metabolized peptide fragments were detected, even at
short times after injection for all peptides. MALDI-TOF MS
revealed a major cleavage site in all gastrin derivatives
between Asp and Phe-NH2 at the C-terminal end of the
peptide.
Clinical studies with radiolabelled CCK2R-binding ligands
In the past few years, several studies in MTC patients have
been performed with both gastrin-like [5, 22, 36–38] and
CCK-like [39] peptides. The evaluation of
111In-DTPA-
CCK8[Nle
3,6] in patients was reported by Kwekkeboom et
al. [39]. The results showed high background activity levels
in the scintigraphic images, relatively low uptake in the
strongly CCK receptor-positive stomach and a rapid degra-
dation of
111In-DTPA-CCK8[Nle
3,6] in the serum. Although
confirmed MTC lesions could be visualized in two patients,
small MTC lesions could not be detected.
Behr et al. reported a clinical pilot study with
111In-
DTPA-MG0 in four MTC patients [5]. They found CCK2
receptor targeting in physiologically CCK2 receptor-
expressing tissues (e.g. the stomach) as well as in metastatic
MTC lesions. In 2002, Behr and Béhé reported a clinical
study using
111In-DTPA-MG0 for both imaging (75 MTC
patients) and therapy (8 MTC patients) [36, 40]. In the
Fig. 1 SPECT/CT images of
mice with subcutaneous A431-
CCK2R tumours 1 h after injec-
tion of
111In-labelled (a) DOTA-
sCCK8, (b) DOTA-sCCK8
[Phe
2(p-CH2SO3H),Nle
3,6] and
DOTA-MG0 as a reference.
Radiotracer uptake is clearly
visible in the A431-CCK2R
tumours (arrows), whereas no
uptake is observed in the mock-
transfected A431 tumours
(arrowheads)
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111In-DTPA-MG0 was
injected and whole-body scans were performed at several
time-points after injection. They found that normal organ
uptake was restricted to the stomach and the kidneys. In
patients with known disease, all tumours known from con-
ventional imaging modalities were visualized as early as 1 h
after injection, although optimal scans were obtained at 24 h
after injection. More importantly, in 29 out of the 32 MTC
patients with occult disease, at least one lesion was visual-
ized. Uptake in the liver and spleen was very low.
Gotthardt et al. reported a tumour detection rate of 87%
by scintigraphy using
111In-DTPA-MG0 in a group of
26 MTC patients [37]. Most of the patients in that study,
however, had known metastases and in the group of patients
with occult disease, tumour lesions were found in only one.
Recently, Fröberg et al. investigated and compared
99mTc-
Demogastrin 2, evaluated earlier in vitro and in vivo by
Nock et al. [22], with
111In-DOTA-CCK8 and
111In-
DOTA-MG11 [38]. In an earlier study by this group [41],
radiolabelling conditions were optimized and preclinical
aspects of the compounds were investigated.
99mTc-Demo-
gastrin 2 showed the best tumour visualization, which may
have been due to better imaging properties of
99mTc com-
pared to those of
111In.
99mTc-Demogastrin 2 visualized all
known lesions in six MTC patients, whereas with the other
two compounds several known lesions were missed. In
addition, in four patients, new lesions in the neck, brain,
bone and liver were discovered with
99mTc-Demogastrin 2.
Both
111In-DOTA-CCK8 and
111In-DOTA-MG11 were
shown to be less suitable for scintigraphy as the sensitivity
as well as the uptake in visible lesions were limited and
appeared to be insufficient for radionuclide therapy in these
tumours. Moreover, the stability of
111In-DOTA-MG11 was
poor. Although this peptide was reported to be stable in
ex vivo human serum, in this study HPLC analysis of
blood samples from patients showed that 10 min after
administration, only 10% of the original peptide was still
intact.
99mTc-Demogastrin 2 was more stable, illustrated by
the fact that more than 60% of the radioligand was still intact
at the same time-point. Therefore, it was concluded that
99mTc-Demogastrin 2 appears to be a promising diagnostic
tool in patients with MTC.
GLP-1 peptides
GLP-1 is an intestinal hormone that stimulates insulin se-
cretion through receptors expressed on islet cells. GLP-1
receptors are expressed mainly in the pancreas, stomach and
brain. In addition, these receptors are also abundantly over-
expressed on >90% of insulinomas at a mean density twice
that of SSTR type 2 (SSTR2) [42, 43]. To investigate the
feasibility of radiolabelled GLP-1 for the detection of
insulinomas, tumour-targeting studies have been performed
with radioiodinated GLP-1 and the GLP-1 receptor antago-
nist exendin-3 [44]. Studies were performed in rats bearing
rat insulinoma RINm5F tumours. GLP-1(7–36)amide and
exendin-3 were labelled with
125I. Although with both pep-
tides the tumours could be visualized, the antagonist per-
formed better. Radioiodinated GLP-1 was rapidly degraded
in vivo (<10 min) , whereas the
125I-exendin-3 showed
better stability in vivo. Therefore, it was concluded that
GLP-1 antagonists, such as exendin-3, might be suitable
tracers for scintigraphic imaging of insulinomas. In a second
study, the GLP-1 analogue exendin-4 was synthesized with
an additional Lys residue at position 40, allowing site-
specific conjugation of DTPA. Biodistribution of
111In-la-
belled exendin-4 was studied in mice and rats. Specific
uptake was observed in receptor-positive organs such as
the stomach, pancreas, lungs and adrenals. High uptake
was seen in the kidneys. Tumour targeting of
111In-DTPA-
[Ahx-Lys
40]exendin-4 was studied in transgenic Rip1Tag2
mice which spontaneously develop insulinomas. Due to the
high GLP-1 receptor expression in these tumours, the tumour
uptake was very high (287±62%ID/g at 4 h after injection).
Tumours as small as 1 mm could be detected by multipinhole
SPECT imaging [45].
More recently, Brom et al. investigated the potential of
PET imaging using DOTA-[Lys
40]-exendin-3 [46]. In nude
mice with subcutaneous rat insulinoma INS-1 tumours
68Ga-DOTA-[Lys
40]-exendin-3 was compared to
111In-
DTPA-[Lys
40]-exendin-3. The IC50 values of both com-
pounds were similar and were in the low nanomolar range.
Remarkably, tumour uptake of
68Ga-DOTA-[Lys
40]-exen-
din-3 was significantly lower than that of
111In-DTPA-
[Lys
40]-exendin-3 at 1 h after injection (25.1±7.2%ID/g
vs. 8.9±3.1%ID/g, respectively). Despite this lower uptake,
small subcutaneous tumours could be visualized by PET/CT
imaging, and the authors considered that clinical studies
should be conducted to investigate the potential of
68Ga-
DOTA-[Lys
40]-exendin-3 for insulinoma imaging in humans.
A similar study has been performed comparing
111In-
DOTA[Ahx-Lys
40]exendin-4,
68Ga-DOTA[Ahx-Lys
40]
exendin-4 and
99mTc-EDDA/HYNIC[Ahx-Lys
40]exendin-4
in Rip1Tag2 mice [47]. The
99mTc-labelled compound
showed a significantly lower tumour uptake than the
111In
and
68Ga-labelled peptides. Dosimetry calculations revealed
that
111In-DOTA[Ahx-Lys
40]exendin-4 resulted in the highest
effective dose (extrapolated to humans, 155 μSv/MBq),
whereas the effective dose of
68Ga-DOTA[Ahx-Lys
40]exen-
din-4 and
99mTc-EDDA/HYNIC [Ahx-Lys
40]exendin-4 were
much lower (32 μSv/MBq and 3.7 μSv/MBq, respectively).
Recently, a novel GLP-1 analogue, EM3106B, was la-
belled with
18F using N-2-(4-
18F-fluorobenzamido)ethylma-
leimide (
18F-FBEM) [48]. This compound was synthesized
in a 25% yield in 60 min. The IC50 value for the GLP-1
S82 Eur J Nucl Med Mol Imaging (2012) 39 (Suppl 1):S78–S92receptor was 1.07±0.84 nM, which was similar to that of the
unlabelled compound, but approximately fivefold better than
the IC50 of GLP-1. In vivo studies in INS-1 tumour-bearing
mice revealed high (28.5±4.7%ID/g) and specific tumour
uptake at 1 h after injection which could be clearly visualized
by microPET imaging. Specific uptake was also noted in the
pancreas, spleen, stomach and intestine.
Clinical studies with radiolabelled GLP-1R-targeting
peptides
The feasibility of
111In-DTPA[Ahx-Lys
40]exendin-4 for
clinical use was first demonstrated in two patients with
insulinoma [49]. After this proof of concept, a clinical study
with an exendin peptide for insulinoma imaging was per-
formed in six patients by the groups in Basel and Bern [50].
They used
111In-DOTA[Ahx-Lys
40]exendin-4 in patients
with proven endogenous hyperinsulinaemic hypoglycaemia.
A peptide dose of 30 μg (82–97 MBq) was injected and
SPECT/CT scans were recorded at 20 min, and 4 and 23 h
after injection. In all six patients, a nadir in glucose levels
occurred at 40 min after injection. In three patients, an
exogenous glucose infusion was necessary. Blood sampling
revealed a biexponential blood clearance with approximate-
ly 70% of the administered dose cleared in the alpha phase.
The clearance occurred exclusively via the kidneys. In four
of the six patients, the tumour could be clearly visualized at
4 h after injection, while in two patients the tumours could
only be visualized in late scans (3–7 days), most likely due to
their location close to the kidneys. The authors also showed
that the in vivo determination of GLP-1R using
111In-DOTA
[Ahx-Lys
40]exendin-4 correlated with in vitro autoradiogra-
phy and histology analysis of GLP-1R. Finally, it was dem-
onstrated that the intraoperative use of a gamma probe 2–
14 days after injection of
111In-DOTA[Ahx-Lys
40]exendin-4
was highly beneficial for the in situ localization of tumours.
Recently, GLP-1R targeting with
111In-DTPA[Ahx-
Lys
40]exendin-4 was compared to SSTR2 targeting of
68Ga-DOTA-TATE PET/CT in patients with suspected insu-
linoma [51]. Of the 11 patients studied, GLP-1R targeting
was positive in four, while SSTR2 targeting was positive in
eight. In one patients both receptors were expressed. It was
concluded that, in contrast to benign insulinomas, malignant
insulinomas do not always express GLP-1R, but more often
express SSTR2. They always express one of the two
receptors.
CXCR4-binding peptides
Chemokines are small proteins (8–14 kDa) that chemoat-
tract leucocytes by binding to cell surface receptors, chemo-
kine receptors. In 1996, one of these receptors, CXCR4, was
identified as a coreceptor for the entry of T-cell line-tropic
HIV-1 [52]. Later, it was found that CXCR4 and its ligand,
stromal cell-derived factor-1 (SDF-1), also play an impor-
tant role in tumour metastasis [53]. Müller et al. [53]
reported that CXCR4 is highly expressed in breast cancer
and SDF-1 ishighly expressed in organs representing the first
destinations of metastasis. Moreover, they demonstrated that
neutralization with anti-CXCR4 monoclonal antibody signif-
icantly inhibits the metastasis of breast cancer cells in mice.
Similar results were obtained in other types of cancer (see
reference [54] for review). Based on these findings, several
groups exploited targeting of CXCR4 as a potential tool for
the imaging of metastatic tumours.
The first study in which the development of an
111In-
labelled CXCR4 targeting peptide was investigated was
published in 2006 [54]. Based on the previously discovered
T22 peptidic CXCR4 inhibitor a DTPA-conjugated labelled
analogue was designed. This cyclic peptide, designated
DTPA-Az-TZ14011 was stabilized by amidation at the C-
terminus and N-terminally acetylated. The authors showed
that
111In-DTPA-Tz-14011 had an IC50 for CXCR4 of 7.9
nM. An in vivo study in tumour-bearing mice demonstrated
specific targeting in the tumour, with tumour-to-blood ratios
increasing from 1.31±0.14 at 1 h after injection to 5.65±
2.68 at 24 h. High and specific uptake was noted in the liver
and spleen, which could be attributed to the high expression
of CXCR4 mRNA in mice.
Based on this compound, a radiofluorinated peptide was
developed [55]. The peptide was labelled with
18F using the
well-established [
18F]SFB method in a 50–60% decay-
corrected yield. The IC50 value as determined in CXCR4-
transfected CHO cells was 2.5 nM. Biodistribution in mice
bearing CHO-CXCR4 tumours revealed moderate uptake in
the tumour (2.3±0.7%ID/g) which was not significantly
higher than in the CXCR4-negative control tumour (1.7±
0.9%ID/g). Relatively high uptake was found in CXCR4-
rich organs such as the spleen and bone marrow. Remark-
ably high blood levels were found, with the majority of the
radiolabelled peptide (94.5%) in the red blood cell fraction.
Association of the peptide with red blood cells in the circu-
lation most likely resulted in a decreased availability of the
peptide to bind to CXCR4 in the tumour.
More recently, a non-peptidic CXCR4 inhibitor was
radiolabelled with
64Cu [56]. In this inhibitor, AMD3100,
the two cyclam moieties are linked by a 1,4-phenylenebis
(methylene) bridge. AMD3100 has been identified as a
specific inhibitor of CXCR4. AMD3100 was originally
developed as an inhibitor of HIV. It was also found to inhibit
SDF-1-induced chemotaxis through CXCR4, suggesting
that it might also be used to inhibit cancer metastasis. One
of the cyclam rings was used to radiolabel the compound
with
64Cu. Biodistribution was studied in non-tumour-
bearing mice. High uptake was noted in the liver and
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spleen, lymph nodes and bone marrow. This compound
was also tested in mice with human cancer xenografts
[57]. Proof of principle of CXCR4 imaging with [
64Cu]
AMD3100 was shown in mice bearing CXCR4-transfected
U87MG tumours. PET/CT imaging revealed high and spe-
cific uptake (35%ID/g at 90 min after injection) in the
tumour as well as significant uptake in the liver, kidneys
and bladder. Similar results were found in a CXCR4-
expressing orthotopic MDA-MB-231 breast cancer model.
Most importantly, lung metastases derived from the same
breast cancer tumour could be visualized by PET/CT imag-
ing. Weiss et al. reported similar results with [
64Cu]
AMD3100 in mice with transfected tumours in the liver
and lungs [58]. Although promising, the bicyclam
AMD3100 has a relatively low affinity (approximately
650 nM). In search of agents that are amenable to structural
modification, the same group investigated the monocyclam
analogue AMD3465 to image CXCR4 expression. Com-
pared with the previous compound, AMD3465 has higher
affinity, and reduced size and charge [59]. Despite the
improved affinity and kinetics, [
64Cu]AMD3465 also shows
considerable liver uptake. Some of this liver uptake might
be attributed to possible transchelation of
64Cu from [
64Cu]
AMD3465 to proteins such as superoxide dismutase and
ceruloplasmin. Clinical studies with these peptides have
not been published.
Gastrin-releasing peptide receptor-targeting peptides
BN is a 14-amino-acid C-terminally amidated peptide of
amphibian origin with the sequence Glu
1-Gln
2-Arg
3-Leu
4-
Gly
5-Asn
6-Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Leu
13-Met
14-
NH2 (see Table 1). Gastrin-releasing peptide (GRP) is its 27-
amino-acid human counterpart which shares the seven C-
terminal amino acids with BN. There are three BN mamma-
lian receptor subtypes, namely BB1 (formerly designated as
the neuromedin B receptor), BB2 (formerly designated as
the GRP receptor, GRPR) and BB3 (the orphan receptor, for
which the native ligand has yet to be identified). BN and
GRP both bind with high affinity to GRPR, the subtype
found to be most frequently expressed in tumours [60]. This
receptor is overexpressed in some common tumour types
such as carcinomas of the prostate and breast as well as
small-cell lung cancer, renal cell carcinoma and gastrointes-
tinal stromal tumours (GIST) [60–62]. For this reason, much
of the research effort has focused on high-affinity ligands of
GRPR. These ligands are generally analogues of full-length
BN(1–14) or are truncated analogues based on the C-
terminal amino acid sequence (BN(7–14)) which confers
receptor binding affinity.
Preclinical studies with radiolabelled BN analogues
A recurrent theme in the development of
99mTc-labelled
BN analogues is their tendency to be somewhat lipo-
philic and to clear via the hepatobiliary pathway (thus
hindering imaging in the abdominal region). Baidoo et
al. described the synthesis of
99mTc diaminodithiol con-
jugates of Lys
3-BN [63]. Subsequent work by this group
involved modifications of this compound to reduce the
lipophilicity of these analogues to allow scintigraphy of
the abdominal region, introducing DTPA into the se-
quence as a hydrophilic pharmacokinetic modifier [64,
65]. Thegroup ofVolkerthas usedP2S2[66,67]a n dN 3SB N
(7–14) conjugates [68] using different carbon chain spacers
between the Tc-binding moiety and the peptide. Smith et al.
showed that a spacer of three to eight carbon atoms could be
used without compromising the agonist binding affinity of the
99mTc-N3S-X-BN(7–14)NH2 constructs [68]. Van de Wiele et
al. demonstrated the clinical utility of these compounds using
a
99mTc-N3S-Gly-5-Ava-BN(7–14) developed by Resolution
Pharmaceuticals, Canada (
99mTc-RP527) (see Table 1)[ 69],
but again hepatobiliary excretion of this compound made
imaging in the abdominal areas problematic [70]. Nock et al.
investigated a series of compounds, one based on a GRPR
antagonist as well as four other GRPR agonists. Demobesin 1
is based on the potent antagonist [D-Phe
6, Leu-NHEt
13,des-
Met
14]BN(6–14) [71], to which they attached an open chain
tetraamine (N4) chelator for labelling with
99mTc. Although
this compound showed minimal internalization in prostate
cancer cells, it demonstrated very high and persistent uptake
inPC-3human xenografts innudemice(15.61±1.19%ID/gat
4h )[ 72]. Using the tetraamine chelator, four further agonist
compoundsweredeveloped:[N4
0,Pro
1,Tyr
4]BNanditsNle
14-
substituted analogue (Demobesin 3 and 4) as well as two
truncated BN analogues, [(N4-Bzdig)
0]BN(7–14) and its
Nle
14-substituted analogue, using a benzylaminodiglycolic
acid spacer between the chelator and the receptor-binding
sequence (Demobesin 5 and 6) [73]. All these compounds
showed high receptor affinity (IC50 <0.06 nM in competition
binding assays) and rapid internalization (about 75 % within
30 min) in PC-3 tumour cells. In vivo, Demobesin 3 and 4
demonstrated high tumour uptake (9–11%ID/g at 1 h, 7–9%
ID/gat4 h after injection) withrapid clearance fromnontarget
tissues. These compounds proved to be much less lipophilic
than the truncated BN analogues and are excreted mainly via
the kidneys. The two truncated analogues, Demobesin 5 and
6, showed lower tumour uptake and largely hepatobiliary
clearance. Due to the higher tumour uptake and favourable
excretion route, clinical trials have been started on the Demo-
besin 4 compound. A
99mTc-EDDA/HYNIC-[Lys
3]BN com-
pound has been developed by Ferro-Flores et al. [74].
Although this compound shows predominantly renal excre-
tion, it has relatively low uptake in PC-3 tumours in vivo.
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[
99mTc(H2O)3(CO)3]
+ precursor. La Bella et al. demonstrat-
ed high binding affinity for the GRP receptor, and rapid
internalization into PC-3 cells, of their [
99mTc(CO)3-Nα-
histidinylacetate]BN(7–14) compound; however, tumour
uptake was low and no blocking was seen. Since uptake
into the pancreas was high and specific, the authors specu-
lated that this was due to weak vascularization of the tumour
xenografts. This group developed another tricarbonyl tech-
netium BN conjugate: [
99mTc(I)-PADA-AVA]BN(7–14),
which demonstrated hepatobiliary clearance in vivo and
relatively low (but specific) tumour uptake [75]. Stabiliza-
tion of the peptide sequence and insertion of hydrophilic
spacers to counteract the lipophilicity of the [
99mTc
(CO)3((NαHis)Ac)] chelate led to the development of
[
99mTc(CO)3((NαHis)Ac)]-X-(Cha
13,Nle
14)B N ( 7 –14)
(where Cha is cyclohexylalanine) where the most hydro-
philic spacer Lys(sha)-βAla–βAla- (where sha is shikimic
acid) gave the highest tumour uptake 3.2%ID/g at 1.5 h in
PC-3 tumours in mice as well as the highest tumour-to-
nontumour ratios compared with compounds without
spacers or stabilized peptide sequence [76–78]. This group
further investigated the effect of glycation and charge on
lipophilicity, tumour uptake and tumour-to-nontarget tissue
ratios [79, 80]. Smith et al. also used tricarbonyl
99mTc
complexes such as [
99mTc(X)(CO)3-Dpr-SSS-BN(7–14)
NH2] (where X is H2O or P(CH2OH)3 and DPr is diamino-
propionic acid), and demonstrated specific uptake in PC-3
tumour xenografts of 3.7±0.9%ID/g at 1 h after injection
(better than that of the
99mTc-N3S conjugate in the same
animal model) [68, 81]. More recently, this group has found
tumour uptakes of these derivatives in T47-D breast cancer
xenografts of up to 3.7±1.8%ID/g at 1 h [82], and also
found that insertion of PEG5 or PEG8 into the spacer had
no significant effect on tumour retention. On the other hand,
Dapp et al. found that the incorporation of PEG5 into their
((NαHis)Ac)-X-(Cha
13,Nle
14)BN(7–14) derivative had a
positive effect on pharmacokinetics [83].
In parallel with this work on
99mTc-labelled BN ana-
logues, other workers have been developing radiolabelled
BN analogues using chelators such as DTPA and DOTA for
radiolabelling with trivalent radiometals such as
111In and
67Ga for SPECTand
68Ga and
86Y for PET imaging, as well
as
177Lu for therapy. The Rotterdam group investigated a
number of
111In-radiolabelled DTPA conjugates of BN (both
agonists and antagonists), selecting an agonist [
111In-DTPA-
Pro
1,Tyr
4]BN (termed
111In-MP2248) based on its level of
uptake into GRPR-positive cells and tissues [84, 85]. Sub-
sequently, this group developed a DOTA analogue [
111In-
DOTA-Pro
1,Tyr
4]BN (termed MP2346) which displayed
better target-to-blood ratios and uptake in GRPR-
expressing tissues than the DTPA analogue [86]. Further
Table 1 Overview of GRPR-targeting peptides
BN analogue Reference Radionuclide Chelator/labelling
moiety
Spacer Peptide sequence
BN pGlu
1-Gln
2-Arg
3-Leu
4-Gly
5-Asn
6-Gln
7-Trp
8-Ala
9-Val
10-
Gly
11-His
12-Leu
13-Met
14-NH2
RP527 [69, 70]
99mTc N3S Gly-5-Ava Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Leu
13-Met
14-NH2
Demobesin-1 [72]
99mTc N4 Bzdig Asn
6-Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Leu-NHEt
13
Demobesin-4 [73]
99mTc N4 Bzdig Pro
1-Gln
2-Arg
3-Tyr
4-Gly
5-Asn
6-Gln
7-Trp
8-Ala
9-Val
10-Gly
11-
His
12-Leu
13-Met
14-NH2
[Cha
13Nle
14]
BN(7–14)
[76, 77]
99mTc(CO)3 (NαHis)Ac Lys(Sha)-βAla-
βAla
Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Cha
13-Nle
14-NH2
MP2346 [86]
111In,
68Ga DOTA – Pro
1-Gln
2-Arg
3-Tyr
4-Gly
5-Asn
6-Gln
7-Trp
8-Ala
9-Val
10-Gly
11-
His
12-Leu
13-Met
14-NH2
BZH2 [89]
111In DOTA γ-aminobutyric
acid
D-Tyr
6-Gln
7-Trp
8-Ala
9-Val
10-βAla
11-His
12-Thi
13-Nle
14-NH2
DOTA-PESIN [90]
67/68Ga,
111In DOTA PEG4 Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Leu
13-Met
14-NH2
AMBA [92]
67/68Ga,
177Lu,
111In
DOTA Gly-4-
aminobenzyl
Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Leu
13-Met
14-NH2
RM1 [95]
177Lu,
111In DOTA Gly-4-
aminobenzyl
Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Sta
13-Leu-NH2
NO2A-8Aoc-
BN(7–4)
[106]
64Cu NO2A 8-Aoc Gln
7-Trp
8-Ala
9-Val
10-Gly
11-His
12-Leu
13-Met
14-NH2
[FB-Lys
3]BN [112]
18F SFB – pGlu
1-Gln
2-Lys
3-Leu
4-Gly
5-Asn
6-Gln
7-Trp
8-Ala
9-Val
10-
Gly
11-His
12-Leu
13-Met
14-NH2
BAY-86-4367 [117]
18F
+N(CH3)3 Ala(SO3)-Ala
(SO3)-Ava
Gln
7-Trp
8-Ala
9-Val
10-NMeGly
11-His
12-Sta
13-Leu-NH2
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sequence and inserting non-natural amino acids to develop
MP2653, [
111In-DTPA-ACMpip
5,Tha
6,βAla
11,Tha
13,Nle
14]
BN(5–14), where ACMpip is the cationic spacer 4-
aminocarboxymethyl-piperidine and Tha is β-(2-thienyl)
alanine. This resulted in higher uptake in PC-3 xenografts
than seen with [
111In-DTPA-Pro
1,Tyr
4]BN DTPA [87].
Similar to their work on
99mTc-labelled BN analogues
[68], Hoffman et al. investigated the effect of spacer length
using
111In-DOTA-labelled peptides of the structure:
[DOTA-X]BN(7–14), where X represents a spacer contain-
ing 0, 3, 5, 8 or 11 carbon atoms. They found that the [
111In-
DOTA-8-Aoc]BN(7–14) analogue had higher affinity in
vitro in PC-3 cells as well as the highest uptake in normal
pancreas in vivo. Uptake in PC-3 tumours was 3.63±1.1%
ID/g at 1 h [88].
A different approach was taken by Zhang et al. [89] who
developed DTPA- and DOTA-γ-aminobutyric acid-[D-
Tyr
6,β-Ala
11,Thi
13,Nle
14]BN(6–14) derivatives (BZH1 and
BZH2) that target all three human receptors (i.e. GRPR,
NMB-R and BB3) based on their concomitant expression
in some tumour types [60]. However, relatively low serum
stability was seen for [
111In]BZH1 and [
111In]BZH2 and this
was coupled with relatively fast tumour washout [89, 90].
67Ga-DOTA-PEG2-[D-Tyr
6,β-Ala
11,Thi
13,Nle
14]BN(6–14)
was also evaluated in AR42J tumour-bearing mice (5.26±
1.3%ID/g in tumour) [91]. Zhang et al. went on to evaluate
67Ga-DOTA-PEG4-BN(7–14) (DOTA-PESIN) which
proved to have higher and more prolonged tumour uptake
than the pan-BN analogues in PC-3 tumour-bearing nude
mice (8.77±1.88%ID/g at 4 h) [90].
As is the case when there are several groups working in
the field, it becomes difficult to compare studies carried out
in different centres using xenografts arising from cells at
differing passage numbers in different mouse models. Still,
the Rotterdam group has compared their full-length DOTA-
BN analogue MP2346 and their truncated DTPA-BN ana-
logue MP2653 with three of the most promising compounds
from other groups (as judged by uptake in prostate cancer
tumours) under standardized conditions: [
111In]DOTA-
PESIN, [
111In]AMBA (DOTA-glycyl-4-aminobenzoyl BN
(7–14)) [92] and the antagonist [
99mTc]Demobesin-1.
[
99mTc]Demobesin-1 performed the best as a potential im-
aging agent followed by [
111In]AMBA and [
111In]DOTA-
PESIN, both of which could be used for imaging or PRRT
[93]. Clinical studies of [
99mTc]Demobesin-1 are currently
being carried out in Rotterdam.
The unparalleled tumour targeting ability of the
99mTc-
Demobesin-1 antagonist has led others to work on radio-
labelling antagonists with trivalent metals. These are usually
des-Met
14 analogues of BN with modifications at Leu
13
which affect their affinity for GRPR. For example, the
111In-labelled DOTA-aminohexanoyl-[D-Phe
6,Leu-
NHCH2CH2CH3
13,des-Met
14]BN(6–14) (Bomproamide)
developed by Abd-Elgaliel et al. [94] showed rapid and high
uptake in PC-3 tumours in SCID mice (6.90±1.06%ID/g)
whilst internalization into PC-3 cells in vivo was only 14%
(compared with 25% for Demobesin-1 which has a C-
terminal Leu-NHCH2CH3
13). Mansi et al. developed an
antagonist,
111In-RM1, for comparison with the potent ago-
nist
111In-AMBA. These two compounds have the same
chelator and linker and differ only in that the antagonist is
a des-Met
14 analogue with an inserted statyl group at BN
(13) [95]. Despite lower GRPR affinity (Kd of 8.5±2.7 nM
for the
natIn-RM1 antagonist vs. 0.6±0.3 nM for the ago-
nist),
111In-RM1 showed higher tumour uptake than
111In-
AMBA (13.4±0.8%ID/g vs. 3.69±0.74%ID/g at 4 h) with
better tumour-to-normal tissue ratios. This group went on to
develop a further antagonist molecule with a positively
charged linker (which they postulated would increase affin-
ity), i.e. DOTA-4-amino-1-carboxymethyl-piperidine-D-
Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (RM2) [96].
Although the affinity of
natIn-RM2 was higher (Kd of 2.9±
0.4 nM) than that of
natIn-RM1, the only significant im-
provement in vivo was due to lower liver uptake, leading to
higher tumour-to-liver ratio. In addition to higher tumour
uptake than the agonist BN derivatives and slower washout
from tumours, the antagonists overall have shown much
faster relative clearance from the pancreas and other abdom-
inal GRPR receptor-expressing organs [94–96], and thus
have more favourable tumour-to-normal tissue ratios.
Due to the ready availability of the
68Ga positron emitter
(t1/2068 min) through the
68Ge/
68Ga generator system, a
number of DOTA-conjugated BN derivatives have been
evaluated preclinically as
68Ga-PET diagnostic imaging
agents in tumour models at 1 h [90, 91, 95–98]. The antag-
onist compounds in particular show very high tumour-to-
normal tissue ratios at early time-points [95, 96], which is
advantageous for imaging with
68Ga. Recently, the prostate
tumour-targeting properties of
68Ga-labelled DOTA-G-4-
aminobenzoyl BN(7–14) (AMBA) (a BN agonist) and
18F-
methylcholine (
18F-FCH) have been directly compared in
nude mice bearing VCaP human tumour xenografts, and
68Ga-AMBA peptide targeting was found to be superior to
the metabolism-based
18F-FCH targeting [97].
The development of BN analogues for diagnostic imag-
ing using
64Cu PET has been dominated by the need to
develop chelators that are stable to in vivo transchelation
of the Cu(II) to liver and blood proteins, and this has
recently been the subject of an editorial by Hoffman and
Smith [99]. Although both DOTA and TETA (1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) were
used as chelators for radiolabelling BN analogues with
64Cu [100–103], high background due to transchelation
was seen, leading to the development of more stable ana-
logues mainly based on 1,4,7-triazacyclononane-1,4,7-
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tives of TETA, i.e. CB-TE2A [107]. Smith and coworkers
have developed [
64Cu-NO2A-8-Aoc]BN(7–14) and com-
pared it with [
64Cu-TE2A-8-Aoc]BN(7–14) and [
64Cu-
DO2A-8-Aoc]BN(7–14) [99, 104]. The NO2A analogue
was found to be superior for imaging in PC-3 tumour-
bearing SCID mice. However, when the same group com-
pared a range of
64Cu-NO2A-X-BN(7–14) derivatives in
which X represented different linkers,
64Cu-NO2A-
AMBA-BN(7–14) (where AMBA is para-aminobenzoic
acid) had higher PC-3 tumour uptake (6.05±1.15%ID/g at
1 h) and more rapid clearance from nontarget tissues than
[
64Cu-NO2A-8-Aoc]BN(7–14), possibly due to the more
hydrophilic nature of the linker [108]. Following on from
their work on
64Cu-DOTA-BN(7–14) peptides containing
different amino acid linkers [109], Lears et al. have recently
used Sar-Ar (1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaa-
zabicyclo[6.6.6]-eicosane-1,8-diamine) [110]a sas t a b l e
chelator for Cu(II) [111]. They conjugated Sar-Ar to BN
using succinic acid (SA), 8-aminooctanoic acid (Aoc), gly-
cine and serine to form linkers. While the tumour uptake of
64Cu-SarAr-SA-Aoc-BN(7–14) and
64Cu-SarAr-SA-Aoc-
GSG-BN(7–14) in PC-3 tumours in mice was high (13.0±
0.9%ID/g and 8.5±0.8%ID/g at 1 h, respectively) and com-
parable with that seen for the best of the radiolabelled BN
agonists, there was no improvement in tumour-to-normal
tissue ratios due to slower clearance from the normal tissues
than other
64Cu-BN analogues [111]. The clearance from
blood, liver, tumour and pancreas was faster for the analogue
with the more hydrophilic GSG-containing linker, and it may
be that investigation of more hydrophilic linkers would im-
prove this molecule. To date there have yet to be any studies
published on the use of
64Cu-labelled BN antagonists.
A few
18F-BN derivatives (both agonists and antagonists)
have been developed and evaluated [103, 112–119]. Zhang
et al. radiofluorinated a full-length ([Lys
3]BN) and a trun-
cated derivative Aca-BN(7–14) (where Aca is aminocaproic
acid) using N-succinimidyl-4-
18F-fluorobenzoate (
18F-SFB)
reacted at the Lys or the Aca amino groups, respectively.
They found the [
18F-FB-Lys
3]BN derivative to be superior
to the Aca analogue in terms of affinity, PC-3 tumour uptake
(5.94±0.78%ID/g at 60 min) and pharmacokinetics [112].
This group went on to develop
18F-BBN-RGD heterodimers
for targeting coexpressed GRPR and αvβ3 integrin in pros-
tate cancer cells [103, 114, 115, 119]. Their
18F-FB-PEG3-
Glu-RGD-BN molecule showed 4.00±0.08%ID/g in PC-3
tumours with more rapid clearance from the kidney than a
derivative without PEG3 in the linking moiety [114].
In a collaboration between the Centre for Radiopharma-
ceutical Sciences of ETH, PSI and USZ, Switzerland and
Bayer Schering Pharma, Hohne et al. developed a one-step
18F-labelling process which involved the incorporation of a
lipophilic silyl labelling moiety into an antagonist BN
structure (similar to the
111In/
68Ga-labelled RM1 and RM2
above) to give [
18F]2-(4-(di-tert-butylfluorosilyl)phenyl)
acetyl-Arg-Ava-Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-
NH2 [113], where Ava is 5-aminopentanoic acid. However
this molecule showed low tumour uptake and substantial
hepatobiliary clearance and the group focused on develop-
ing derivatives with a less-lipophilic benzonitrile one-step
labelling moiety and inserting polar spacers between the
labelling moiety and the binding sequence. They found that
the negatively charged derivative, 3-cyano-4-
18F-fluoro-
benzoyl-Ala(SO3H)-Ava-Gln-Trp-Ala-Val-NMeGly-His-
Sta-Leu-NH2 had much higher uptake in PC-3 tumours
(4.88±0.36%ID/g) than the corresponding positively
charged analogue (3-cyano-4-
18F-fluoro-benzoyl-Arg-Ava-
Gln-Trp-Ala-Val-NMeGly-His-Sta-Leu-NH2)[ 116]. To fur-
ther increase the hydrophilicity of this compound, an addi-
tional Ala(SO3H) moiety was inserted into the spacer, and
this compound (termed
18F-BAY-86-4367) showed subna-
nomolar GRPR binding affinity, behaving as an antagonist.
High tumour uptake (6.19±2.49%ID/g in PC-3 xenografts)
was seen with fast, predominantly renal clearance (about
70%) and better tumour-targeting properties than either
18F-
FCH or
18F-FDG [117].
Clinical studies with radiolabelled BN analogues
The first clinical studies on radiolabelled BN derivatives
were carried out by van de Wiele et al. using
99mTc-N3S-
Gly-5-Ava-BN(7–14) (
99mTc-RP527) [69]. Planar and
SPECT images were acquired and tumour uptake was seen
in four of six breast cancers (as well as low diffuse uptake in
normal breast) and one of four androgen-resistant bone-
metastasized prostate carcinomas with good tumour-to-
normal tissue ratios [69]. Primarily renal, and to a lesser
extent, hepatobiliary excretion of this compound was seen
[70]. The rights to RP527 were acquired by Bracco Diag-
nostics who went on to develop
177Lu-AMBA for PRRT
[92]. The latter compound has been the subject of a phase I
clinical trial which has thus far only been published in
abstract form [120]. SPECT imaging with
177Lu-AMBA in
seven patients with hormone-refractory prostate cancer
showed lesions in five of the seven patients. High pancreatic
uptake was also seen. Scopinaro et al. reported the detection
of breast cancer using dynamic and static planar imaging of
cys-(6-amino-n-hexanoic acid)-BN(2–14) (termed [Leu13]
BN) [121] modified on its N-terminus to directly bind
99mTc
[122]. In five patients with primary breast cancer, five of
five primary tumours were visualized at 3 h with
99mTc
[Leu
13]BN, as well as axillary involvement in two of the
five patients. Again diffuse uptake in normal breast was
seen, but tumour-to-normal breast tissue ratios were better
than those seen with
99mTc-sestamibi [121]. In addition,
dynamic planar and SPECT images were acquired in ten
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mas). All eight patients with prostate cancer were positive
and pelvic lymph node involvement was correctly detected
in three patients [123]. Neither patient with benign adenoma
showed uptake. In a dynamic, planar and SPECT study of
colorectal cancer in 13 patients carried out by the same
group, 11 cancers were detected using
9mTc[Leu
13]BN
[124]. However, little information has been given about
the mode of excretion or uptake of this compound in normal
tissues. To address the question as to whether or not GRPR
are present in human pancreas, four patients underwent
planar and dynamic scintigraphy with the agonist
111In-
MP2248 ([
111In-DTPA-Pro
1,Tyr
4]BN) and the antagonist
99mTc-Demobesin 1. Clear pancreatic uptake was seen for
both compounds suggesting the presence of GRPR [125].
Clinical studies of a pan-BN derivative termed
68Ga-
DOTABOM, GABA-[D-Tyr
6,β-Alal
11,Thi
13,Nle
14]BN(6–
14) [126], or BZH2, have been published in abstract form
and summarized by Hofmann et al. [127] and Maecke et al.
[128]. PET scans in 11 patients with prostate cancer were
performed. Primary tumours were visible in all patients as
well as lymph node metastases in three patients. Pancreatic
uptake was seen in four patients and clearance was predom-
inantly renal with >75%ID recovered in the urine at 60 min.
A similar pan-BN compound, DOTA PEG2-[D-Tyr
6,β-
Ala
11,Thi
13,Nle
14]BN(6–14),
68Ga-BZH3, was compared
with
18F-FDG in 17 patients with GIST [129]. Of the 17
patients, 7 were positive for uptake of
68Ga-BZH3 (8/30
lesions) whereas 14 were positive for
18F-FDG (25/30
lesions). One recurrent GIST in the stomach showed
positive
68Ga-BZH3 uptake but was negative for
18F-
FDG. Enhanced uptake of
68Ga-BZH3 was seen in the
pancreas of all patients. The median tumour SUV values
were 3.3 and 7.9 for
68Ga-BZH3 and
18F-FDG, respec-
tively. The authors concluded that
68Ga-BZH3 may be diag-
nostically useful in a subset of patients with GIST in whom
viabletumourissuspectedbut
18F-FDG is negative. The same
authors have recently evaluated
68Ga-BZH3 and
18F-FDG
dynamicPETinpatientswithrecurrentgliomasincomparison
with grading. Of 15 patients, 10 showed enhanced
68Ga-
BZH3 uptake visually while 6 showed enhanced
18F-FDG
metabolismvisually. Theyconcludedthat
68Ga-BZH3may be
helpful in differentiating between low- and high-grade recur-
rent gliomas.
The antagonist BN derivative,
18F-BAY-4367 has recent-
ly been compared to
18F-FEC (
18F-ethyl-choline), one of the
diagnostic PET imaging agents for recurrent prostate cancer
in Europe. Both recurrent and primary prostate cancers (five
patients each) were imaged.
18F-BAY-4367 showed uptake
in one of the five patients with recurrent disease, compared
to positive uptake in four of the five using
18F-FEC. Of the
five patients with primary disease, three were positive for
18F-BAY-4367, while
18F-FEC was able to delineate
malignant lesions in all four of the patients imaged.
18F-
BAY-4367 was safe and well tolerated. The authors con-
cluded that
18F-BAY-4367 is not reliable for PETimaging of
recurrent disease, but is able to visualize primary tumours in
a subset of patients [130]. This conclusion is consistent with
the recent finding that GRPR are overexpressed in primary
prostate cancer but that this overexpression drops in high-
grade or advanced disease [131]. It is clear that the androgen
regulation of GRPR in prostate cancer is a factor that needs
to be further understood to fully utilize these GRPR-
targeting radiopharmaceuticals [132].
Conclusion
A wide series of radiolabelled peptide analogues targeting
receptors specifically expressed on tumours are under inves-
tigation. This is mainly due to the success achieved with
somatostatin analogues, increasing knowledge about receptor
expression and advances in the radiochemistry and peptide
chemistry. The majority of these new peptides have been
evaluated only in animal models, aiming to optimize in vivo
stability, target affinity and target-to-nontarget ratios. Clinical
studies have generally been performed in small numbers of
patients, mainly to investigate the feasibility of these radio-
labelled peptides.
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